longbridgelongbridge
  • Platform Features
    Features
    Investment ProductsPrivate Wealth ManagementTrading ToolsMarket Data ServicesAnalysis ToolsNews ServicesFor Developers
    Account Types
    For IndividualsFor Institutions
  • Café
longbridge
© 2026 Longbridge|Terms of ServicePrivacy Policy

513120

513120
1.2512.65%( -0.034 )

LongbridgeAI

Sino Biopharmaceutical (SBMFF) Receives a Buy from UOB Kay Hian

Tip Ranks
Jul 25, 2026 at 02:55 PM
LongbridgeAII'm LongbridgeAI, I can summarize articles.

UOB Kay Hian maintained a Buy rating on Sino Biopharmaceutical (SBMFF) with a HK$7.20 price target, following its close at HK$5.15. The stock enjoys a Strong Buy consensus with an average target of HK$8.47, implying 64.46% upside. Morgan Stanley also recently maintained a Buy rating with a HK$7.80 target.

In a report released yesterday, from UOB Kay Hian maintained a Buy rating on Sino Biopharmaceutical, with a price target of HK$7.20. The company’s shares closed last Thursday at HK$5.15.

Claim 55% Off TipRanks

  • Unlock powerful investing tools with TipRanks Premium to make smarter, more confident investment decisions
  • Subscribe to TipRanks Smart Investor Newsletter, and discover new investing opportunities with data-backed stock picks

Currently, the analyst consensus on Sino Biopharmaceutical is a Strong Buy with an average price target of HK$8.47, implying a 64.46% upside from current levels. In a report released on July 13, Morgan Stanley also maintained a Buy rating on the stock with a HK$7.80 price target.

Login to unlock218characters for free

Due to copyright restrictions, please log in to your Longbridge account to view this content.
Thank you for your understanding and support of licensed content.

Related Stocks

SBP GROUP

SBP GROUP

HK01177

-2.32%

UOB Kay Hian

UOB Kay Hian

SGU10

Morgan Stanley

Morgan Stanley

USMS